Tandem Diabetes Care (TNDM) AI Stock Analysis

• Market Cap: $1.73B
• Dividend Yield: N/A
• Average Volume (3M): 2.17M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.02
• Revenue Growth: 17.87%
• EPS Growth: -57.03%
• Country: US
• Employees: 2,650
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): >-0.01
• Shares Outstanding: 68,325,930
• 10 Day Avg. Volume: 4,284,685
• 30 Day Avg. Volume: 2,168,788
• PEG Ratio: -0.07
• Price to Book (P/B): 9.53
• Price to Sales (P/S): 1.46
• P/FCF Ratio: -49.85
• Enterprise Value/Market Cap: 1.26
• Enterprise Value/Revenue: 2.15
• Enterprise Value/Gross Profit: 4.00
• Enterprise Value/Ebitda: -12.51
• 1Y Price Target: $29.80
• Price Target Upside: 17.79% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 17
• EPS Forecast (FY): -0.76
• Revenue Forecast (FY): $1.08B

• Rating: 45 Neutral
• Price Target: $28.00 ▲(10.67% Upside)
• Action: Reiterated Date: 02/20/26
• Date: Action: Reiterated 02/20/26

The score is held down primarily by weak financial quality (ongoing losses, higher leverage, and renewed cash burn). Technicals also remain bearish despite oversold signals. These negatives are partly offset by a more positive earnings outlook and improving margins, but near-term headwinds from the PayGo transition limit confidence.

Positive Factors

Installed base & revenue growth

Tandem achieved durable top-line scale, passing $1.0B in FY2025 with an installed base of ~325k and accelerating pump shipments. A large, growing installed base supports recurring consumable demand and provides a multi-year foundation for predictable reorder revenue and customer retention.

Margin expansion and improving profitability

Gross margins have meaningfully expanded (54% FY2025; Q4 58%) and management guides 56–57% for 2026, targeting ~60% by Q4. Sustained margin improvement implies better operating leverage and product mix benefits, making future adjusted EBITDA and eventual consistent profitability more attainable.

Recurring consumables & strategic pharmacy shift

Tandem’s business relies on recurring supplies; shifting to a pharmacy PayGo model aims to convert upfront pump revenue into longer, stickier supply streams with higher reimbursement. If executed, this structurally raises recurring revenue predictability and lifetime customer value.

Negative Factors

Rising leverage

Leverage has climbed sharply, compressing equity and raising default and refinancing risk if losses persist. With ROE deeply negative (~-132% in 2025), elevated debt reduces financial flexibility for R&D, international rollouts, and absorbing execution setbacks without dilutive or costly financing.

Cash flow volatility and return to burn

After intermittent positive quarters, cash generation reversed in 2025 to modest operating and free cash flow deficits. Persistent volatility in converting sales to cash limits self-funding of the PayGo and international transitions and increases reliance on external capital during multi-year strategic shifts.

Execution risk from strategic transitions

The intentional shift to PayGo and moving international sales direct introduces multi-quarter revenue recognition headwinds and operational complexity. These structural transitions may depress near-term reported revenue and require sustained execution and investment across sales, reimbursement and supply channels.

Tandem Diabetes Care Business Overview & Revenue Model

Company Description

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

How the Company Makes Money

Tandem Diabetes Care generates revenue primarily through the sale of its insulin delivery devices, including the t:slim X2 insulin pump and associated supplies such as infusion sets and cartridges. The company operates on a direct sales model, selling products to healthcare providers, diabetes clinics, and directly to consumers. Additionally, Tandem benefits from partnerships with insulin manufacturers and healthcare systems that facilitate the integration of its products with other diabetes management solutions. Revenue is also supported by reimbursement from insurance companies, which cover a portion of the costs for patients using Tandem's devices. Furthermore, the company's ongoing innovation and product development efforts allow it to maintain a competitive edge, potentially leading to increased sales and market share.

Tandem Diabetes Care Financial Statement Overview

Summary

Revenue growth and gross margin have improved, but the business remains unprofitable with widening net losses, rising leverage (higher debt-to-equity), and a return to negative operating/free cash flow in 2025—overall indicating elevated financial risk despite better top-line momentum.

Income Statement

Revenue growth has re-accelerated meaningfully (2024: ~26%, 2025: ~77%), and gross margin has improved to ~54% in 2025 from ~49% in 2023, suggesting better scale and/or product mix. However, profitability remains weak: net losses widened in 2025 (net margin ~-20% vs ~-10% in 2024) and operating profitability is still negative. Overall, strong top-line momentum is being offset by continuing losses and margin volatility below gross profit.

Balance Sheet

Leverage has risen and equity has compressed: debt-to-equity increased to ~2.86x in 2025 from ~1.80x in 2024 and ~0.95x in 2022, reflecting a weaker capital cushion. Returns on equity are deeply negative (2025 ROE ~-132%), consistent with sizable losses relative to the equity base. While total assets remain substantial, the balance sheet trend points to higher financial risk and reduced flexibility if losses persist.

Cash Flow

Cash generation has deteriorated into cash burn in 2025, with operating cash flow turning slightly negative (about -$10M) and free cash flow also negative (about -$30M), reversing 2024’s modestly positive free cash flow. Cash flow has been volatile over the period (strongly positive in 2021, negative in 2023, modestly positive in 2024, then negative again in 2025). A positive note is that free cash flow is less negative than net income in 2025, but the overall pattern suggests uneven conversion of earnings into cash and limited near-term self-funding capacity.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.01B	940.20M	747.72M	801.22M	702.80M
Gross Profit	530.85M	489.57M	367.69M	412.99M	376.21M
EBITDA	-174.70M	-99.13M	-196.46M	-74.21M	34.06M
Net Income	-204.71M	-96.03M	-222.61M	-94.59M	15.57M
Balance Sheet
Total Assets	881.11M	967.66M	952.66M	1.05B	905.14M
Cash, Cash Equivalents and Short-Term Investments	292.67M	438.33M	467.91M	616.90M	623.81M
Total Debt	444.48M	473.56M	415.67M	419.88M	314.67M
Total Liabilities	725.94M	704.56M	639.03M	612.84M	472.02M
Stockholders Equity	155.17M	263.10M	313.63M	439.95M	433.11M
Cash Flow
Free Cash Flow	-29.67M	4.99M	-58.61M	16.37M	87.85M
Operating Cash Flow	-9.72M	24.23M	-31.81M	50.46M	111.36M
Investing Cash Flow	72.88M	-23.48M	-85.74M	33.17M	-186.88M
Financing Cash Flow	-43.37M	8.37M	4.11M	16.88M	51.93M

Tandem Diabetes Care Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 25.30
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TNDM, the sentiment is Positive. The current price of 25.3 is above the 20-day moving average (MA) of 21.27, above the 50-day MA of 21.44, and above the 200-day MA of 17.69, indicating a bullish trend. The MACD of 1.46 indicates Negative momentum. The RSI at 63.77 is Neutral, neither overbought nor oversold. The STOCH value of 66.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TNDM.

Tandem Diabetes Care Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DXCM	77 Outperform	$28.26B	35.09	34.50%	―	14.21%	5.66%
EW	75 Outperform	$50.22B	47.87	10.43%	―	0.19%	65.58%
MDT	71 Outperform	$125.38B	27.26	9.38%	2.76%	5.34%	13.15%
PODD	68 Neutral	$17.36B	70.45	18.12%	―	27.12%	-41.72%
PHG	64 Neutral	$30.35B	29.94	―	3.30%	-0.76%	-55.03%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TNDM	45 Neutral	$1.73B	-8.24	-97.88%	―	17.87%	-57.03%

Tandem Diabetes Care Corporate Events

Tandem Diabetes Care Updates Bylaws, Tightens Governance Rules

On December 26, 2025, Tandem Diabetes Care’s board of directors approved Amended and Restated Bylaws as part of a periodic governance review, immediately replacing the prior bylaws. The revisions significantly update advance notice requirements for shareholder director nominations and other proposals, tightening disclosure obligations, limiting the number of nominees to the seats up for election, restricting substitute nominees, and enabling the company to disregard nominations if shareholders fail to comply with federal proxy rules or do not appear to present their nominees. Additional changes formalize the board’s authority to cancel, reschedule or postpone shareholder meetings, reserve the white proxy card exclusively for the board, modernize indemnification and notice provisions in line with Delaware corporate law, simplify and clarify voting standards for director elections, and remove the requirement to provide a physical shareholder list at meetings. Collectively, these amendments streamline corporate governance, reinforce the board’s control over the shareholder meeting and proxy process, and may shape how activist investors and other shareholders engage with the company in future contested or routine elections.

The most recent analyst rating on (TNDM) stock is a Hold with a $24.00 price target. To see the full list of analyst forecasts on Tandem Diabetes Care stock, see the TNDM Stock Forecast page.